MAP2K7 and cancer: The first FDA-approved MEK inhibitor for cancer therapy, trametinib has been shown as a RAF/MEK heterodimer breaker, which binds to the interface of MEK and impairs RAF/MEK association as well as subsequent phosphorylation of MEK by RAF[76,180,181].